VOLUNTARY ANNOUNCEMENT - ALMB-0166 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA FOR THE TREATMENT OF PARKINSON'S DISEASE

Hong Kong Exchanges and Clearing Limited and The Stock Excha nge of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoe ver for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this ann ouncement. CSPC PHARMACEUTICAL GROUP LIMITED (Incorporated in Hong Kong with limited liability) (Stock Code: 1093) ʮ ̡ VOLUNTARY ANNOUNCEMENT ALMB-0166 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA FOR THE TREATMENT OF PARKINSON ’S DISEASE The Board of Directors (the ‘‘Board ’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company ’’, together with its subsidiaries, the ‘‘Group ’’) is pleased to announce that ALMB-0166 developed by the Group has obtained approval from the National Medical Produ cts Administration of the People ’s Republic of China to conduct a Phase II clinical trial in Chin a to evaluate its efficacy in patients with Parkinson ’s disease. ALMB-0166, a first-in-class humanized monoclonal antibod y inhibitor targeting a novel hemichannel membrane protein, Connexin 43 (Cx43), was independently de veloped by the Company ’s subsidiary, AlaMab Therapeutics Inc., for the treatment of Parkinson ’s disease, acute ischemic stroke, acute spinal cord injury, and other neurological disorders. Parkinson ’s disease is the world ’s second most common neurodegenerative disorder, characte rized pathologically by the progressive degeneration of dopamin ergic neurons in the substantia nigra and the formation of Lewy bodies. The etiology of Parkinson ’s disease remains incompletely understood. Its clinical manifestations are notable for motor symptoms suc h as resting tremors, muscular rigidity, bradykinesia, and postural instability, as well as non-mot or symptoms including sleep disorders, cognitive impairment, and psychiatric disturbances. Both motor and non-motor symptoms worsen as the disease progresses, severely affecting patients ’ quality of life and imposing heavy economic and caregiving burdens on families and society. Currently, the rapeutic drugs and approaches for Parkinson ’s disease, including levodopa-based therapies, only provid e symptomatic relief without reversing disease progression or achieving a cure. Therefore, given the limit ations of current therapeutic approaches, there is an urgent need in the field of Parkinson ’s disease for the development of novel therapeutic drugs and approaches to effectively delay disease progress ion and improve patients ’ quality of life. – 1 – ALMB-0166 exerts its effect by targeting Cx43 hemichannels , inhibiting the release and spread of neuroinflammatory mediators, and thereby maximizing neur oprotection. Preclinical studies in subacute and chronic Parkinson ’s disease animal models demonstrated that ALMB-0166 signif icantly prevented dopamine depletion in the brain, markedly restored behavio ral performance and functional capacity, and exhibited a favorable dose-response relationship. The Group will make every effort to advance the clinical deve lopment of ALMB-0166 across multiple indications and strive to bring it to the market as early as po ssible. By Order of the Board CSPC Pharmaceutical Group Limited CAI Dong Chen Chairman Hong Kong, 15 September 2025 As at the date of this announcement, the Board comprises Mr. C AI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chu nlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Steph en and Ms. LI Quan as Independent Non-executive Directors. – 2 –

The release as fetched from its publisher. irasia.com ↗